We use our antibody technologies to develop and engineer optimized chimeric antigen receptor (CAR) to re-direct T cells to eliminate a wide array of tumor types.

CAR immune cell therapy is based on the engineering and selective ex vivo expansion of immune cells derived from patient peripheral blood and consists of four key steps:

  1. Harvesting the immune cells from a patient’s or donor’s blood
  2. Genetically engineering the immune cells to express cancer-specific CARs
  3. Increasing the number of engineered immune cells through ex vivo expansion
  4. Infusing the functional cancer-specific immune cells into the patient

This process allows us to engineer and expand immune cells from the blood of cancer patients and make them highly effective at recognizing and killing cancer cells through engagement of the CARs. We are further exploring the use of the CAR technology to engineer NKT cells derived from healthy donors to produce an allogeneic off-the-shelf CAR product to treat cancer patients.